Did You Know...
...that while attempting to develop a super strong glue, 3M employee Spencer Silver accidentally developed a glue that was so weak it would barely hold two pieces of paper together? However, his colleague Art Fry needed the glue. Fry sang with his church choir and marked the pages of his hymnal with small scraps of paper that often fell out. He used Silver's glue to hold the papers in place. Today we call this invention Post-it Notes.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7972607 | Attenuated francisella and methods of use Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated Francisella mutan... | 07/05/2011 |
| 7695725 | Modified free-living microbes, vaccine compositions and methods of use thereof Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modif... | 04/13/2010 |
| 7691393 | attenuated for entry into non-phagocytic cells, vaccines comprising the , and methods of use thereof The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated... | 04/06/2010 |
| 7419676 | Activatable recombinant neurotoxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 09/02/2008 |
| 7381700 | Methods for treating pain associated with arthritis A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin ty... | 06/03/2008 |
| 7364745 | Development of a live, attenuated, recombinant vaccine for Brucellosis A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure... | 04/29/2008 |
| 7361352 | Influenza immunogen and vaccine A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably e... | 04/22/2008 |
| 7354592 | Genetically modified tumor-targeted bacteria with reduced virulence The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically mod... | 04/08/2008 |
| 7351416 | Vaccines comprising acapsular deletion mutants Acapsular hyaE deletion mutants of P. multocida can be administered to mammals, particularly ungulates, or birds to provide protective immunity against wild-type P. multocida, e.g., to prevent or reduce the severity of hemorrhagic septicemia or pneumon... | 04/01/2008 |
| 7348138 | Method of inducing cell death using West Nile virus capsid protein This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from... | 03/25/2008 |
| 7297339 | mutants and vaccines comprising same Mutant strains of Rhodococcus equi are disclosed, and vaccines comprising same. ... | 11/20/2007 |
| 7297340 | Vaccine and method for preventing biofilm formation The present invention is directed to compounds and methods for immunizing a patient against a biofilm-producing bacterial infection and a vaccine related thereto. ... | 11/20/2007 |
| 7285276 | antigens and corresponding DNA fragments and uses thereof The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein... | 10/23/2007 |
| 7226588 | Non-toxic mutants of pathogenic gram-negative bacteria A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a m... | 06/05/2007 |
| 7192596 | Recombinant toxin fragments A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be tran... | 03/20/2007 |
| 7189398 | Broad spectrum pyrogenic exotoxins antagonists and vaccines The invention relates to peptides having an amino acid sequence substantially homologous to an amino sequence of a domain of a pyrogenic exotoxin, which domain forms a central turn in the exotoxin starting within β-strand 7 and connecting the β-strand 7, via short... | 03/13/2007 |
| 7138126 | Transformed A method for modifying a wild strain of an entero-invasive Shigella to produce a modified strain of Shigella that can be used for making a vaccine against the wild strain of Shigella. The genome of the wild strain of Shigella is transform... | 11/21/2006 |
| 7091176 | Methods for treating arthritis pain A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin ty... | 08/15/2006 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 7063852 | Hybrid LT-A/CT-B holotoxin for use as an adjuvant The present invention provides a novel composition which is a hybrid heat labile enterotoxin comprising the A-subunit of the heat labile toxin of Escherichia coli (LT-A) and the B-subunit of the cholera enterotoxin of Vibrio cholerae (CT-B). The hybrid... | 06/20/2006 |
| 7060277 | Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins The invention relates to peptides comprising an amino acid sequence homologous to the amino sequence of a fragment of a pyrogenic exotoxin, and functional derivatives of said peptides, capable of eliciting protective immunity against toxic shock induced by a pyrogen... | 06/13/2006 |
| 7052860 | Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans. ... | 05/30/2006 |
| 7045122 | vaccine The present invention relates to live attenuated Salmonella strains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates t... | 05/16/2006 |
| 6979449 | Acellular immunogenic compositions and acellular vaccine compositions against The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis ... | 12/27/2005 |
| 6936258 | Staphylococcus antigen and vaccine A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus | 08/30/2005 |
| 6923972 | Methods for use of genetically modified tumor-targeted bacteria with reduced virulence The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmon... | 08/02/2005 |
| 6905691 | Vaccines containing attenuated bacteria The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of ran... | 06/14/2005 |
| 6863894 | Genetically modified tumor-targeted bacteria with reduced virulence The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically mod... | 03/08/2005 |
| 6844423 | Compositions and methods for regulating bacterial pathogenesis The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimul... | 01/18/2005 |
| 6833135 | DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system The present invention discloses a DNA fragment that can direct the insertion of heterologous DNA into a specific site (tRNAAla gene) of Mycobacterium spp. genome. This DNA fragment includes the attachment site region (attP) and the integrase gene o... | 12/21/2004 |
| 6818219 | Reagent for detecting and monitoring viral infections The invention concerns a reagent for diagnosing an infection caused by a virus, characterized in that it comprises essentially a mixture consisting of (1) an immunodominant fragment of a protein of said virus comprising not more than 60 aminoacids, preferably betwee... | 11/16/2004 |
| 6793927 | Construction of Pasteurella haemolytica vaccines Methylation of DNA can be a critical step in the introduction of DNA into P. haemolytica. A methyltransferase has been isolated and molecularly cloned for this purpose. Use of the methyltransferase has allowed construction of defined, attenuated mutants for u... | 09/21/2004 |
| 6787360 | Bacteriophage, a process for the isolation thereof, and a universal growth medium useful in the process thereof The present invention provides a isolated bacteriophage useful as a tool for studying biological, biochemical, physiological and genetic properties of actinomycetes and other organisms which comprises a novel strain of Saccharomonospora having certain specified char... | 09/07/2004 |
| 6770275 | Live attenuated RTX-producing bacteria of the family pasteurellaceae The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of... | 08/03/2004 |
| 6676942 | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia... | 01/13/2004 |
| 6660840 | Methods for enhancement of protective immune responses Methods for eliciting or enhancing immune responses to antigens, including tumor antigens, and/or DNA vaccines are provided. The methods employ polypeptides or nucleic acid compositions that contain at least a biologically active portion of a Leishmania b... | 12/09/2003 |
| 6656478 | Cross-protective salmonella vaccines The present invention relates to a method of protecting pigs against disease caused by infection by heterologous serotypes of Salmonella including but not limited to S. typhimurium comprising administering to the pigs a modified live vaccine incorporating... | 12/02/2003 |
| 6610307 | Immunity against pasteurella haemolytica leukotoxin Bovine respiratory disease (BRD) complex, shipping fever, or pneumomic pasteurellosis, is a multifactorial disease whereby a combination of viral infection, adverse environment and poor immune status may combine to predispose animals to bacterial infectio... | 08/26/2003 |
| 6562348 | Recombinant M. tuberculosis auxotrophic for leucine and vaccines using same The present invention provides a recombinant M. tuberculosis mycobacterium that is auxotrophic for leucine. The present invention also provides a vaccine comprising a recombinant M. tuberculosis mycobacterium that is auxotrophic for leucine, as well as a ... | 05/13/2003 |
| 6555331 | Bacteriophage assay There is provided an assay suitable for the typing of bacterial strains. In the assay a predetermined amount of phage is combined with a bacterial isolate of unknown strain, the mixture being located in a suitable container. The mixture of phage and bacte... | 04/29/2003 |
